Comparing Surgical and Endovascular Arteriovenous Fistula Creation
Part of paid clinical trials in Los Angeles, California.
- Sponsor
- University of California, Los Angeles
- Study ID
- NCT05654103
- Status
- Recruiting
Conditions
- End Stage Renal Disease on Dialysis
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 99 Years
- Healthy Volunteers
- Not accepted
Interventions
- endoAVF — DEVICEThe device will be used according to manufactures instructions and medical facilities standard of care. EndoAVF has a high likelihood of requiring additional procedures that would not have been required if they had undergone surgAVF.
- surgAVF — PROCEDUREThe surgAAVF procedure will be done according to the medical facilities standard of care. SurgAVF can also require additional procedures to help with the fistula being useable.
Study Details
Patients with end-stage kidney disease (ESKD) who use hemodialysis to filter their blood require vascular access for the dialysis machine; the most common type of vascular access is called an arteriovenous fistula (AVF). The AVF is a direct connect between an artery and vein. Until recently, AVFs were only created through surgery that requires general anesthesia and opening up the skin. Now there are 2 FDA-approved devices designed to create AVFs using endovascular techniques (endoAVF), which means a device that goes through the skin instead of opening the skin up. Also patients are not required to be under general anesthesia, they can receive local anesthesia instead. Due to the relatively new approval of these devices, there is not a randomized study to compare the results of endoAVF versus surgAVF. This study is a pilot study for an eventually larger scale study to compare the results of endoAVF versus surgAVF. The study aims to determine what the proportion of patients seeking hemodialysis access could qualify for receiving either an endoAVF , surgAVF, or both. Patients who are screened for hemodialysis access must undergo a duplex ultrasound of the blood vessels in the arm to confirm correct sizing. If participants qualify for both procedures they will be randomized to either endoAVF or surgAVF and will track the clinical and patient-reported outcomes of each procedure. Our pilot study hopes to enroll 90 participants. Those outcomes will inform a larger scale study. If the potential participant chooses to abstain from participation in the randomized trial, preferring to decide the method of AVF creation, we will offer to them a chance to join an endoAVF/surgAVF registry that will track the clinical outcomes of the procedure via medical record monitoring.
Key Dates
- Start date
- Nov 20, 2024
- Status verified
- Oct 2025
- Primary completion
- Dec 1, 2027
- Completion
- Jan 1, 2028
Study Design
- Enrollment
- 90 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: surgAVFParticipant will undergo fistula creation through surgical means, which requires undergoing general anesthesia and opening the skin to create the fistula.
- Active Comparator: endoAVFParticipant will undergo fistula creation through endovascular surgical means, which does not require general anesthesia and is created by using a device that goes through the skin to create the fistula. The two devices that are currently FDA approved and used to create the endoAVF are the WavelinQ™ EndoAVF System and the Ellipsys® Vascular Access System.
Primary Outcome Measure
Physiologically mature fistula [ Time Frame: 6 months postoperatively ]
Central Contacts
- Kate Horiuchi, MPH310-267-1039
- Jenny Lester, MPH310-794-9728
Locations (2)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| UCLA Division of Vascular and Endovascular Surgery Clinic | Los Angeles | California | 90095 | |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15231 |
Find similar trials in Los Angeles, CA
Related Studies
- A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With HyperphosphatemiaPHASE2 · Recruiting · R1 Therapeutics · Huntsville, Alabama
- Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal DiseasePHASE4 · Recruiting · Yale University · New Haven, Connecticut
- Fight Fatigue: A Progressive Muscle Relaxation and Walking Intervention to Reduce Fatigue in Adults With ESKDRecruiting · University of Illinois at Chicago · Chicago, Illinois